BACKGROUND: Patients aged >10 years with rhabdomyosarcoma have an inferior outcome compared with patients ages 1 to 9 years, which may be explained by toxicities (adverse events [AEs]) that result in chemotherapy dose reductions. METHODS: AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded. The incidence of toxicities by age and treatment regimen was determined. The odds of developing AEs in a particular age group (ages 5-9 years, 10-14 years, and 15-20 years) were compared with the odds in the control group of patients ages 1 to 4 years. RESULTS: In total, 657 patients were eligible for analysis. The estimated 5-year event-free survival rates were 78%, 83%, 67%, and 58% for the groups ages 1 to 4 years, 5 to 9 years, 10 to 14 years, and 15 to 20 years, respectively. Patients ages 15 to 20 years experienced less neutropenia (odds ratio [OR], 0.43; P < .0001), thrombocytopenia (OR, 0.41; P < .0001), anemia (OR, 0.34; P < .0001), and infection (OR, 0.41; P < .0001) compared with younger patients, although they received similar amounts of chemotherapy. In contrast, peripheral nervous system toxicity was higher in adolescents aged >10 years (OR, 4.18; P < .0001). Females experienced more neutropenia (OR, 1.28; P = .05) and thrombocytopenia (OR, 1.26; P = .06) compared with males. CONCLUSIONS: Adolescents who received treatment for rhabdomyosarcoma experienced significantly less hematologic toxicity and more peripheral nervous system toxicity compared with younger children despite receiving similar amounts of chemotherapy. Although outcomes were inferior in adolescents, it was unclear whether the differences in toxicity observed in the current study had an impact on outcome. The authors concluded that future studies examining the age-related and sex-related differences in pharmacokinetics of chemotherapy are necessary.
BACKGROUND:Patients aged >10 years with rhabdomyosarcoma have an inferior outcome compared with patients ages 1 to 9 years, which may be explained by toxicities (adverse events [AEs]) that result in chemotherapy dose reductions. METHODS:AEs observed during 1 of 3 randomized chemotherapy regimens (vincristine, dactinomycin, and cyclophosphamide [VAC]; vincristine, dactinomycin, and ifosfamide [VAI]; or vincristine, ifosfamide, and etoposide [VIE]) in the Fourth Intergroup Rhabdomyosarcoma Study were recorded. The incidence of toxicities by age and treatment regimen was determined. The odds of developing AEs in a particular age group (ages 5-9 years, 10-14 years, and 15-20 years) were compared with the odds in the control group of patients ages 1 to 4 years. RESULTS: In total, 657 patients were eligible for analysis. The estimated 5-year event-free survival rates were 78%, 83%, 67%, and 58% for the groups ages 1 to 4 years, 5 to 9 years, 10 to 14 years, and 15 to 20 years, respectively. Patients ages 15 to 20 years experienced less neutropenia (odds ratio [OR], 0.43; P < .0001), thrombocytopenia (OR, 0.41; P < .0001), anemia (OR, 0.34; P < .0001), and infection (OR, 0.41; P < .0001) compared with younger patients, although they received similar amounts of chemotherapy. In contrast, peripheral nervous system toxicity was higher in adolescents aged >10 years (OR, 4.18; P < .0001). Females experienced more neutropenia (OR, 1.28; P = .05) and thrombocytopenia (OR, 1.26; P = .06) compared with males. CONCLUSIONS: Adolescents who received treatment for rhabdomyosarcoma experienced significantly less hematologic toxicity and more peripheral nervous system toxicity compared with younger children despite receiving similar amounts of chemotherapy. Although outcomes were inferior in adolescents, it was unclear whether the differences in toxicity observed in the current study had an impact on outcome. The authors concluded that future studies examining the age-related and sex-related differences in pharmacokinetics of chemotherapy are necessary.
Authors: Deborah Tomlinson; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; Lillian Sung Journal: Support Care Cancer Date: 2007-08-28 Impact factor: 3.603
Authors: J S McCune; A Batchelder; K A Guthrie; R Witherspoon; F R Appelbaum; B Phillips; P Vicini; D H Salinger; G B McDonald Journal: Clin Pharmacol Ther Date: 2009-03-18 Impact factor: 6.875
Authors: Archie Bleyer; Ronald Barr; Brandon Hayes-Lattin; David Thomas; Chad Ellis; Barry Anderson Journal: Nat Rev Cancer Date: 2008-04 Impact factor: 60.716
Authors: Iyad Sultan; Ibrahim Qaddoumi; Sameer Yaser; Carlos Rodriguez-Galindo; Andrea Ferrari Journal: J Clin Oncol Date: 2009-04-27 Impact factor: 44.544
Authors: Kenneth K Khamly; Vicky J Thursfield; Michael Fay; Jayesh Desai; Guy C Toner; Peter F M Choong; Samuel Y K Ngan; Gerard J Powell; David M Thomas Journal: Int J Cancer Date: 2009-07-15 Impact factor: 7.396
Authors: Linda Granowetter; Richard Womer; Meenakshi Devidas; Mark Krailo; Chenguang Wang; Mark Bernstein; Neyssa Marina; Patrick Leavey; Mark Gebhardt; John Healey; Robert Cooper Shamberger; Allen Goorin; James Miser; James Meyer; Carola A S Arndt; Scott Sailer; Karen Marcus; Elizabeth Perlman; Paul Dickman; Holcombe E Grier Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Jeannine S McCune; David H Salinger; Paolo Vicini; Celeste Oglesby; David K Blough; Julie R Park Journal: J Clin Pharmacol Date: 2008-10-16 Impact factor: 3.126
Authors: Elysia M Alvarez; Marcio Malogolowkin; Jeffrey S Hoch; Qian Li; Ann Brunson; Brad H Pollock; Lori Muffly; Ted Wun; Theresa H M Keegan Journal: JCO Oncol Pract Date: 2020-06-11
Authors: Abha A Gupta; Yueh-Yun Chi; James R Anderson; Elizabeth Lyden; Brenda Weigel; Carola Arndt; William H Meyer; Abby Rosenberg; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2017-03-23 Impact factor: 3.167
Authors: Lara E Davis; Katherine A Janeway; Aaron R Weiss; Yen-Lin E Chen; Thomas J Scharschmidt; Mark Krailo; Julia L Glade Bender; Lisa M Kopp; Shreyaskumar R Patel; Gary K Schwartz; L Elise Horvath; Douglas S Hawkins; Meredith K Chuk; Denise K Reinke; Richard G Gorlick; R Lor Randall Journal: Cancer Date: 2017-05-11 Impact factor: 6.860
Authors: Naamit Kurshan Gerber; Leonard H Wexler; Samuel Singer; Kaled M Alektiar; Mary Louise Keohan; Weiji Shi; Zhigang Zhang; Suzanne Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-13 Impact factor: 7.038